Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01270438
First received: January 4, 2011
Last updated: October 7, 2013
Last verified: October 2013

January 4, 2011
October 7, 2013
December 2010
August 2011   (final data collection date for primary outcome measure)
Progression-free survival of patients treated with FOLFOX6 plus bevacizumab with or without gamma-secretase inhibitor RO4929097 [ Time Frame: From start of treatment to time of progression, assessed up to 12 months ] [ Designated as safety issue: No ]
Progression is defined as changes in RECIST 1.1-defined imaging, progression in non-target lesions as defined by RECIST 1.1, unequivocal clinical deterioration, or death from any cause.
Progression-free survival of patients treated with FOLFOX6 plus bevacizumab with or without gamma-secretase inhibitor RO4929097 [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01270438 on ClinicalTrials.gov Archive Site
  • Objective response rate (complete or partial response) as measured by RECIST [ Time Frame: Assessed up to 12 months ] [ Designated as safety issue: No ]
    Estimated using the binomial distribution and exact 95% confidence intervals (CI) will be provided.
  • Incidence of dose-limiting and non-dose-limiting toxicities [ Time Frame: Assessed up to 12 months ] [ Designated as safety issue: Yes ]
    Summarized using descriptive statistics.
  • Pharmacokinetics and pharmacodynamics of gamma-secretase inhibitor RO4929097 [ Time Frame: Baseline, and day 1 of courses 1 and 2 ] [ Designated as safety issue: No ]
    Computed using non- compartmental methods for RO4929097 and will be correlated with clinical parameters using Cox regression model for association with survival and PFS and Wilcoxon rank sum test for response.
  • Objective response rate (complete or partial response) as measured by RECIST [ Designated as safety issue: No ]
  • Incidence of dose-limiting and non-dose-limiting toxicities [ Designated as safety issue: Yes ]
  • Pharmacokinetics and pharmacodynamics of gamma-secretase inhibitor RO4929097 [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)

This phase II clinical trial is studying how well giving combination chemotherapy and bevacizumab with or without RO4929097 works in treating patients with metastatic colorectal cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy and bevacizumab is more effective with RO4929097 in treating patients with colorectal cancer.

PRIMARY OBJECTIVES:

I. To estimate the efficacy, as determined by progression-free survival, of FOLFOX6 and bevacizumab with versus without gamma-secretase inhibitor RO4929097 (RO4929097).

SECONDARY OBJECTIVES:

I. To estimate the clinical benefit of RO4929097 in combination with mFOLFOX6 and bevacizumab, as measured by objective response rate.

II. To evaluate the safety and tolerability of RO4929097 in combination with mFOLFOX6 chemotherapy and bevacizumab.

III. To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of RO4929097 in combination with mFOLFOX6 and bevacizumab.

IV. To investigate PD response of RO4929097 in combination with mFOLFOX6 chemotherapy and bevacizumab, as assessed by direct measurement of gamma-secretase enzyme activity, in tumor samples.

V. (Exploratory) To investigate the Notch signaling pathway genes targeted by RO4929097 in combination with mFOLFOX6 chemotherapy and bevacizumab and correlate with clinical outcome.

VI. (Exploratory) To investigate the Ras signaling pathway genes targeted by RO4929097 in combination with mFOLFOX6 chemotherapy and bevacizumab and correlate with clinical outcome.

VII. (Exploratory) To investigate putative colorectal cancer stem cells targeted by RO4929097 in combination with mFOLFOX6 chemotherapy and bevacizumab and correlate with clinical outcome.

OUTLINE: This is a multicenter study. Patients are stratified according to participating center, prior therapy (adjuvant/neoadjuvant vs none), and number of organs* involved by metastases (1 vs > 1). Patients are randomized to 1 of 2 treatment arms.

NOTE: *Lesions all in the liver would be considered as 1 organ involved.

ARM I: Patients receive FOLFOX6 regimen comprising oxaliplatin intravenously (IV) over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46 hours, and bevacizumab IV over 30-90 minutes on days 1-2. Patients also receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10.

Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity (RO4929097 is given for up to 12 courses).

ARM II: Patients receive FOLFOX6 regimen and bevacizumab as in arm I.

Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients may undergo blood sample collection at baseline and periodically during study for pharmacokinetic, pharmacodynamic, and correlative studies.

After completion of study therapy, patients are followed up for 12 months.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Adenocarcinoma of the Colon
  • Adenocarcinoma of the Rectum
  • Recurrent Colon Cancer
  • Recurrent Rectal Cancer
  • Stage IVA Colon Cancer
  • Stage IVA Rectal Cancer
  • Stage IVB Colon Cancer
  • Stage IVB Rectal Cancer
  • Drug: FOLFOX regimen
    Given IV
  • Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
    Given orally
  • Biological: bevacizumab
    Given IV
  • Drug: oxaliplatin
    Given IV
  • Drug: leucovorin calcium
    Given IV
  • Drug: fluorouracil
    Given IV
  • Experimental: Arm I (RO4929097, combination chemotherapy, bevacizumab)
    Patients receive FOLFOX6 regimen comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46 hours, and bevacizumab IV over 30-90 minutes on days 1-2. Patients also receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
    Interventions:
    • Drug: FOLFOX regimen
    • Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
    • Biological: bevacizumab
    • Drug: oxaliplatin
    • Drug: leucovorin calcium
    • Drug: fluorouracil
  • Experimental: Arm II (combination chemotherapy, bevacizumab)
    Patients receive FOLFOX6 regimen and bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
    Interventions:
    • Drug: FOLFOX regimen
    • Biological: bevacizumab
    • Drug: oxaliplatin
    • Drug: leucovorin calcium
    • Drug: fluorouracil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Not Provided
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed adenocarcinoma of the colon or adenocarcinoma of the rectum

    • Metastatic disease by imaging
  • Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20mm by conventional techniques or as ≥ 10 mm by spiral CT scan
  • No known brain metastases
  • ECOG performance status 0-1
  • ANC ≥ 1,500/mm³
  • WBC ≥ 3,000/mm³
  • Platelet count ≥ 100,000/mm³ (without a platelet transfusion ≤ 14 days prior to study)
  • Hemoglobin ≥ 9 g/dL
  • Serum creatinine ≤ 1.5 times upper limit of normal (ULN)
  • Urine protein:creatinine ≤ 0.5 or proteinuria < 1,000 mg on 24-hour urine collection
  • Total bilirubin ≤ 1.5 times ULN
  • AST and ALT ≤ 2.5 times ULN (≤ 5.0 times ULN for patients with liver metastases)
  • Albumin ≥ 2.5 g/dL
  • Amylase ≤ 2 times ULN
  • Lipase ≤ 2 times ULN
  • PTT ≤ 1.2 times ULN
  • INR ≤ 1.2 times ULN
  • No patients with uncontrolled hypophosphatemia, hypocalcemia, hypomagnesemia, hyponatremia, or hypokalemia defined as less than the lower limit of normal for the institution, despite adequateelectrolyte supplementation
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use two forms of contraception (i.e., barrier contraception and one other method of contraception) prior to, during, and for ≥ 12 months after study participation
  • Patients must not have current evidence of or history of another malignancy except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other curatively treated solid tumors with no evidence of disease for ≥ 3 years prior to enrollment
  • Able to swallow capsules
  • No malabsorption syndrome or other condition that would interfere with intestinal absorption
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma-secretase inhibitor RO4929097 used in the study
  • No clinically important history of liver disease, including known viral, other hepatitis, or cirrhosis
  • No uncontrolled intercurrent illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • A history of torsades de pointes or other significant cardiac arrhythmias
    • Psychiatric illness and/or social situations that would limit compliance with study requirements
  • No baseline QTcF > 450 msec (male) or QTcF > 470msec (female)
  • No serious or non-healing wound, ulcer, or bone fracture
  • No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
  • No significant traumatic injury within the past 28 days
  • No clinically significant cardiovascular disease, including any of the following:

    • Inadequately controlled hypertension (systolic BP > 160 mm Hg and/or diastolic BP > 90 mm Hg despite antihypertension medication)
    • History of cerebrovascular accident within the past 6 months
    • Myocardial infarction or unstable angina within the past 6 months
    • NYHA grade II-IV congestive heart failure
    • Serious and inadequately controlled cardiac arrhythmia
  • No requirement for antiarrhythmics or other medications known to prolong QTc
  • No significant vascular disease (e.g., aortic aneurysm, requiring surgical repair, history of aortic dissection, or recent peripheral arterial thrombosis) within the past 6 months
  • No clinically significant peripheral vascular disease
  • No evidence of bleeding diathesis or coagulopathy
  • No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
  • Recovered to < NCI CTCAE grade 2 toxicities related to prior therapy
  • No prior adjuvant or neoadjuvant chemotherapy for colorectal cancers within 12 months of development of metastases
  • No prior chemotherapy or gamma-secretase inhibitors or other investigational agents for metastatic colorectal cancer
  • No prior radiotherapy for colorectal cancers including in the neoadjuvant or adjuvant setting within 12 months of development of metastases
  • No major surgical procedure or open biopsy within the past 28 days and no anticipation of need for major surgical procedures during the course of the study
  • No concurrent medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®)

    • Patients who switch from warfarin sodium to alternative anti-coagulant agents allowed
  • No concurrent medications that are strong inducers, inhibitors, or substrates of CYP3A4, including ketoconazole and grapefruit juice
  • No concurrent combination antiretroviral therapy for HIV-positive patients
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01270438
NCI-2011-02571, NCI-2011-02571, CDR0000692198, MSKCC-10191, 10-191, 8467, U01CA069856, N01CM62206
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Neil Segal Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP